Rigel Pharmaceuticals Q3 2026 Earnings Date & Estimates

Rigel Pharmaceuticals (NASDAQ:RIGL) is a biotechnology company that discovers, develops and commercializes small-molecule medicines for immune and hematologic diseases. Founded in 1996 and headquartered in South San Francisco, California, the company focuses on therapies designed to address significant unmet medical needs in areas including autoimmune disorders, inflammatory conditions and cancer.

Rigel’s marketed products include TAVALISSE (fostamatinib), an oral spleen tyrosine kinase inhibitor approved in the United States to treat adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment. The company also markets REZLIDHIA (olutasidenib), an oral targeted therapy approved for adults with relapsed or refractory acute myeloid leukemia whose cancer cells have a susceptible IDH1 mutation.

The company commercializes its products in the United States and works with regional or international partners to support availability in other markets. Rigel also maintains a research and development pipeline focused on targeted therapies for immune-mediated diseases and hematologic cancers. Raul Rodriguez has served as the company’s president and chief executive officer, providing leadership as Rigel has expanded from a research-focused biotechnology company into a commercial-stage pharmaceutical business.